Loading...
Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
Human epidermal growth factor receptor (HER) 2 (HER2) is overexpressed in 20–30% of breast cancers. HER2 is a preferred target for treating HER2-positive breast cancer. Trastuzumab and pertuzumab are two HER2-targeted monoclonal antibodies approved by the Food and Drug Administration (FDA) to use as...
Na minha lista:
| Udgivet i: | Cancers (Basel) |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6210751/ https://ncbi.nlm.nih.gov/pubmed/30241301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10100342 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|